Orange Book product · Generic (ANDA)
VASOPRESSIN
VASOPRESSIN
At a glance
Jul 18, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 18, 2022
4 yr ago
Today
Pharmaceutical detail
Active ingredient
VASOPRESSIN
Strength
20UNITS/ML (20UNITS/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 211857
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of VASOPRESSIN
- 2024VASOPRESSIN IN SODIUM CHLORIDE 0.9%Brand (NDA)
NDA 217766 · LONG GROVE PHARMS
- 2023VASOPRESSIN IN SODIUM CHLORIDE 0.9%Brand (NDA)
NDA 217569 · BAXTER HLTHCARE CORP
- 2020VASOPRESSINBrand (NDA)
NDA 212593 · AM REGENT
- 2014VASOSTRICTBrand (NDA)
NDA 204485 · PH HEALTH
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212068 · SANDOZ
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212069 · SANDOZ
- 2024VASOPRESSINGeneric (ANDA)
ANDA 213988 · DR REDDYS
- 2024VASOPRESSINGeneric (ANDA)
ANDA 216963 · GLAND
- 2023VASOPRESSINGeneric (ANDA)
ANDA 217987 · CIPLA
- 2023VASOPRESSINGeneric (ANDA)
ANDA 213206 · FRESENIUS KABI USA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 214314 · EUGIA PHARMA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 212944 · AMNEAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
